{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:36:16Z","timestamp":1787168176966,"version":"build-2736575974"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T00:00:00Z","timestamp":1519171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Pilgrim Trust","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Mundipharma Research Ltd","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To explore potential study participants\u2019 views on willingness to join clinical trials of pharmacological interventions for illicit opioid use to inform and improve future recruitment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Qualitative focus group study [six groups: oral methadone (two groups); buprenorphine tablets (two groups); injectable opioid agonist treatment (one group); and former opioid agonist treatment (one group)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings<\/jats:title>\n                    <jats:p>Drug and alcohol services and a peer support recovery service (London, UK).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Forty people with experience of opioid agonist treatment for heroin dependence (26 males, 14 females; aged 33\u201366\u00a0years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>Data collection was facilitated by a topic guide that explored willingness to enrol in clinical pharmacological trials. Groups were audio\u2010recorded and transcribed. Transcribed data were analysed inductively via Iterative Categorization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Participants\u2019 willingness to join pharmacological trials of medications for opioid dependence was affected by factors relating to study burden, study drug, study design, study population and study relationships. Participants worried that the trial drug might be worse than, or interfere with, their current treatment. They also misunderstood aspects of trial design despite the researchers\u2019 explanations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Recruitment of participants for clinical trials of pharmacological interventions for illicit opioid use could be improved if researchers became better at explaining clinical trials to potential participants, dispelling misconceptions about trials and increasing trust in the research process and research establishment. A checklist of issues to consider when designing pharmacological trials for illicit opioid use is proposed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.14163","type":"journal-article","created":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T11:55:20Z","timestamp":1516622120000},"page":"1066-1076","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Improving recruitment to pharmacological trials for illicit opioid use: findings from a qualitative focus group study"],"prefix":"10.1111","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1502-5983","authenticated-orcid":false,"given":"Joanne","family":"Neale","sequence":"first","affiliation":[{"name":"National Addiction Centre King's College London, London  UK"},{"name":"Centre for Social Research in Health University of New South Wales, Sydney  Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-182X","authenticated-orcid":false,"given":"Charlotte N. E.","family":"Tompkins","sequence":"additional","affiliation":[{"name":"National Addiction Centre King's College London, London  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3373-4943","authenticated-orcid":false,"given":"Rebecca","family":"McDonald","sequence":"additional","affiliation":[{"name":"National Addiction Centre King's College London, London  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5413-2725","authenticated-orcid":false,"given":"John","family":"Strang","sequence":"additional","affiliation":[{"name":"National Addiction Centre King's College London, London  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,21]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"211","article-title":"Thoughts on narcotics addiction","volume":"41","author":"Dole V. P.","year":"1965","journal-title":"Bull NY Acad Med"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03410200081030"},{"key":"e_1_2_8_4_1","unstructured":"Center for Substance Abuse Treatment.Medication\u2010assisted treatment for opioid addiction in opioid treatment programs. Treatment improvement protocol (TIP) Series 43. HHS Publication no. (SMA) 12\u20134214. Rockville MD: Substance Abuse and Mental Health Services Administration;2005."},{"key":"e_1_2_8_5_1","unstructured":"World Health Organization (WHO).WHO Model List of Essential Medicines 20th edn.2017. Available at:http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/20th_EML2017.pdf(accessed 9 October 2017) (Archived athttp:\/\/www.webcitation.org\/6u5fDQLej)."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13539"},{"key":"e_1_2_8_7_1","unstructured":"Food and Drug Administration.The drug development process. Step 3: Clinical research.2017. Available at:https:\/\/www.fda.gov\/ForPatients\/Approvals\/Drugs\/ucm405622.htm(accessed 9 October 2017) (Archived athttp:\/\/www.webcitation.org\/6u5fLb6O8)."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000013.pub4"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-6-34"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-14-166"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952999209026069"},{"key":"e_1_2_8_12_1","first-page":"41","article-title":"Why do heroin users refuse to participate in a heroin\u2010assisted treatment trial?","volume":"16","author":"Demaret I.","year":"2014","journal-title":"Heroin Addict Related Clin Prob"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2009.00096.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1747-597X-10-3"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/09595230701829561"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1980.01780150069008"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7489(98)00054-6"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1191\/1463423606pc274oa"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/140349489001800311"},{"key":"e_1_2_8_20_1","unstructured":"ChettiarJ. LockK. Oviedo\u2010JoekesE. SievewrightK. SchechterM.T.The recruitment of participants to the Canadian heroin trial: free heroin is not enough. Poster presentation. Presented at the 19th International Harm Reduction Conference Barcelona Spain 2008."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-6-2"},{"key":"e_1_2_8_22_1","unstructured":"National Institute on Drug Abuse Clinical Trials Network.Improving recruitment and retention R & R tips.2008. Available at:https:\/\/www.drugabuse.gov\/sites\/default\/files\/files\/NIDAR\u2010n\u2010Rweb.pdf(accessed 9 October 2017) (Archived athttp:\/\/www.webcitation.org\/6u5fRycDN)."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0025668"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12200"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540120701866992"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.01230.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13314"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2007.01863.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2009.04.002"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6939-14-28"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14015"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fadd.14163","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.14163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T10:35:57Z","timestamp":1694946957000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.14163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,21]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/add.14163"],"URL":"https:\/\/doi.org\/10.1111\/add.14163","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,21]]},"assertion":[{"value":"2017-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}